Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | VHL | P40337 | 1/20 | 0.35 |
| ▸ | ELOC | Q15369 | 1/20 | 0.35 |
| ▸ | ELOB | Q15370 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1435018 | 0.82 | CA2 (0.48) | CA1CA2TSHRCA12CA4 | |
| SCHEMBL1268562 | 0.80 | ALDH1A1 (0.39) | CA2TSHRLTA4HHPGD | |
| SCHEMBL8779728 | 0.79 | — | — | |
| SCHEMBL885161 | 0.78 | TP53 (0.42) | CA2TSHR | |
| SCHEMBL7049374 | 0.76 | — | — | |
| SCHEMBL5542726 | 0.76 | — | — | |
| SCHEMBL8497901 | 0.76 | — | — | |
| SCHEMBL2851830 | 0.76 | CA1 (0.40) | CA1CA2 | |
| SCHEMBL1940530 | 0.76 | TRPA1 (0.40) | TSHR | |
| SCHEMBL7049379 | 0.76 | HRH3 (0.46) | CA1CA2CA12CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2734516-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Boehringer Ingelheim International GmbH (DE) | 2014-05-28 | — | — | EP | claimed |
| WO-2013012844-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | WO | claimed |
| US-20120029226-A1 | METHOD FOR THE SYNTHESIS OF CHIRAL ALPHA-ARYL PROPIONIC ACID DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2012-02-02 | — | — | US | claimed |
| EP-2393771-A1 | Method for the synthesis of chiral alpha-aryl propionic acid derivatives | DSM IP Assets B.V. (NL) | 2011-12-14 | — | — | EP | claimed |
| WO-2010089343-A1 | METHOD FOR THE SYNTHESIS OF CHIRAL ALPHA-ARYL PROPIONIC ACID DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2010-08-12 | — | — | WO | claimed |
| EP-4695232-A1 | COMPOUNDS AND PROCESSES RELATED TO FLUMETYLSULFORIM | ADAMA MAKHTESHIM LTD. (IL) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024214047-A9 | COMPOUNDS AND PROCESSES RELATED TO FLUMETHYLSULFORIM | ADAMA MAKHTESHIM LTD. (IL) | 2025-05-30 | — | — | WO | disclosed |
| US-20250145598-A1 | ACID CERAMIDASE INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2025-05-08 | — | — | US | disclosed |
| WO-2024214047-A1 | COMPOUNDS AND PROCESSES RELATED TO FLUMETHYLSULFORIM | ADAMA MAKHTESHIM LTD. (IL) | 2024-10-17 | — | — | WO | disclosed |
| EP-4387617-A1 | ACID CERAMIDASE INHIBITORS AND USES THEREOF | The Regents of the University of California (US) | 2024-06-26 | — | — | EP | disclosed |
| WO-2023023156-A1 | ACID CERAMIDASE INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023023156-A1 | ACID CERAMIDASE INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-23 | — | — | WO | disclosed |
| EP-0882715-A1 | NOVEL N-(UNSUBSTITUTED OR SUBSTITUTED)-4-SUBSTITUTED-6-(UNSUBSTITUTED OR SUBSTITUTED)PHENOXY-2-PYRIDINECARBOXAMIDES OR THIOCARBOXAMIDES, PROCESSES FOR PRODUCING THE SAME, AND HERBICIDES | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1998-12-09 | — | — | EP | disclosed |
| EP-0627406-B1 | 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT | YOSHITOMI PHARMACEUTICAL (JP) | 1998-10-28 | — | — | EP | disclosed |
| US-5719176-A | 2-amino-1,3-propanediol compound and immunosuppressant | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1998-02-17 | — | — | US | disclosed |
| US-5604229-A | 2-amino-1,3-propanediol compound and immunosuppressant | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-02-18 | — | — | US | disclosed |
| EP-0627406-A1 | 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1994-12-07 | — | — | EP | disclosed |
| EP-0236880-B1 | Penem derivatives | ERBA CARLO SPA (IT) | 1994-07-20 | — | — | EP | disclosed |
| US-4886793-A | PENICILLINS; HUMANS OR ANIMALS | FARMITALIA CARLO ERBA, S.R.L. (IT) | 1989-12-12 | — | — | US | disclosed |
| EP-0236880-A2 | Penem derivatives | FARMITALIA CARLO ERBA S.r.l. (IT) | 1987-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145598-A1 | ACID CERAMIDASE INHIBITORS AND USES THEREOF | ASAH2, ASAH1, ACER2 | PRSS1 230/4885PRSS2 422/4885PRSS3 358/4885 |
| US-20120029226-A1 | METHOD FOR THE SYNTHESIS OF CHIRAL ALPHA-ARYL PROPIONIC ACID DERIVATIVES | GRIA1, GRIA3, GRIA2 | PRSS1 2703/4885PRSS2 2940/4885PRSS3 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.